• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

How to Stay Safe From Wildfire Smoke
This week, many people who live in the U.S. have woken up to hazy skies. Wildfire smoke from Eastern Canada continues to trail down the East Coast and as far west as Minnesota. State and local authorities have issued air-quality warnings throughout the affected regions, and it could be days before they’re lifted. Wildfire pollution may be a new threat to some of these regions, but with global temperatures climbing, it could be more common in the future. Here’s what to know about staying safe until the smoke clears. [time-brightcove not-tgx=”true”] Adjust your day if you’re most at risk Becau...
Source: TIME: Health - June 7, 2023 Category: Consumer Health News Authors: Haley Weiss Tags: Uncategorized healthscienceclimate Public Health Source Type: news

Penicillin allergy delabelling in pregnancy
CMAJ. 2023 Mar 27;195(12):E452-E453. doi: 10.1503/cmaj.220973.NO ABSTRACTPMID:36972913 | PMC:PMC10042453 | DOI:10.1503/cmaj.220973
Source: Canadian Medical Association Journal - March 27, 2023 Category: General Medicine Authors: Andrea Atkinson Vanessa Poliquin Chelsea Elwood Source Type: research

New STELARA ® (ustekinumab) Long-Term Data Support its Established Safety Profile in Inflammatory Bowel Disease and Durable Efficacy in Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, March 4, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced final pooled long-term safety results for STELARA® (ustekinumab) through five years in adults with moderately to severely active Crohn’s disease (CD) and four years in adults with moderately to severely active ulcerative colitis (UC), as well as final four-year clinical and endoscopic outcomes from the UNIFI long-term extension (LTE) study evaluating the efficacy of STELARA for the treatment of adults with moderately to severely active UC.1,2 These data are a part of Janssen’s 22 oral and poster ...
Source: Johnson and Johnson - March 4, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news

Safety and savings from penicillin allergy de-labelling in pregnancy: good stewardship, good  cents
Studies have shown that 80-95% of pregnant patients who report a penicillin allergy can be safely de-labelled. A pencillin allergy has been associated with poor obstetric outcomes, low rates of appropriate antibiotic prescribing and additional healthcare system costs. In a cohort of patients in British Columbia, Canada, who underwent penicillin de-labelling in pregnancy we present safety data and calculations of the lifetime savings following de-labelling.
Source: American Journal of Obstetrics and Gynecology - January 13, 2023 Category: OBGYN Authors: Atkinson A, Zhang BY, Mak R, Paquette V, Dionne F, Watt M, Erdle S, Van schalkwyk J, Wong T, Poliquin V, Elwood C Source Type: research

Science ’s 2022 Breakthrough of the Year: A telescope’s golden eye sees the universe anew
html { scroll-behavior: smooth; } .news-article-content--featured>.bodySection>.mb-2x:not(:first-of-type) { display: none; } h3 { scroll-margin-top: 5rem; } .parent-section h3, .subsection h3 { font-size: 1.375rem; line-height: 1.875rem; } .news-article-content-footer h2 { display: none; } .toc img { padding-bottom: 16px; transition: opacity .25s; } .toc img:hover { opacity: 60%; } .toc .image-grid img { padding-bottom: 16px; padding-top: 16px; } .image-grid .news-article__figure__image__wrapper:before, .image-grid .news-article__figure__image__wrapper:after { display: none; } .news-article-content sectio...
Source: ScienceNOW - December 15, 2022 Category: Science Source Type: news

STELARA ® (ustekinumab) Demonstrated Sustained Symptomatic and Corticosteroid-Free Remission Through Four Years in Adults with Moderately to Severely Active Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced final data from the long-term extension (LTE) of the Phase 3 UNIFI study demonstrating efficacy and safety of STELARA® (ustekinumab) through four years of treatment in adult patients with moderately to severely active ulcerative colitis (UC).1 Among all patients who had achieved clinical responsea with STELARA during induction, 64.9 percent were in symptomatic remissionb after 44 weeks of maintenance. At week 200 (four years), this proportion of patients was 55.2 percent; the majority (96.4 percen...
Source: Johnson and Johnson - October 10, 2022 Category: Pharmaceuticals Source Type: news

Janssen Presents Study Results Showing Clinical Efficacy for TREMFYA ® (guselkumab) and Long-Term Safety Profile for STELARA® (ustekinumab) for Patients Living with Inflammatory Bowel Disease at Digestive Disease Week® 2022
SPRING HOUSE, PENNSYLVANIA, May 24, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 2 GALAXI 1 clinical trial of TREMFYA® (guselkumab) in adult patients with moderately to severely active Crohn’s disease (CD), and from three separate long-term pooled analyses of adult patients with ulcerative colitis (UC) and CD treated with STELARA® (ustekinumab).1,2,3,4 These data are being presented as oral and poster presentations and are among 29 Janssen abstracts presented during the Digestive Disease Week® (DDW) meeting taking place in person and virtually in San Di...
Source: Johnson and Johnson - May 24, 2022 Category: Pharmaceuticals Source Type: news

Improving Intrapartum Group B Streptococcus Prophylaxis in Patients with a Reported Penicillin or Cephalosporin Allergy: A Quality Improvement Project
CONCLUSIONS: Implementation of standardized allergy-guided prophylaxis safely improved appropriate β-lactam antibiotic use in obstetric patients requiring GBS prophylaxis who reported penicillin and cephalosporin allergies.PMID:35338006 | DOI:10.1016/j.jogc.2022.02.128
Source: Journal of Obstetrics and Gynaecology Canada : JOGC - March 26, 2022 Category: OBGYN Authors: Linda X Li Cyndy Oliver Stefania Ronzoni Arthur Zaltz Jerome A Leis Marion Elligsen Philip W Lam Source Type: research

Janssen Reports Positive Topline Week 48 Phase 2 Results for TREMFYA ® (guselkumab) in Adults With Moderately to Severely Active Crohn's Disease
SPRING HOUSE, PENNSYLVANIA, November 17, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced topline results from the Phase 2 GALAXI 1 clinical trial which showed rates of clinical remission (Crohn’s Disease Activity Index [CDAI]<150) previously reported at week 12 increased at week 48 among adults with moderately to severely active Crohn’s disease (CD) treated with TREMFYA® (guselkumab).1 At week 48, 65 percent of patients receiving TREMFYA achieved clinical remission. TREMFYA is under investigation and not currently approved for the treatment of CD in the U.S.2Janssen previously...
Source: Johnson and Johnson - November 17, 2021 Category: Pharmaceuticals Source Type: news

Pages: 1  2  3